Interleukin-21 in cancer immunotherapy: Friend or foe?
Interleukin (IL)-21, a cytokine produced by activated conventional CD4+ T lymphocytes and Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is also pro-inflammatory in many tissues and promotes colitis-associated colon cancer. Understanding the biology of IL-21...
Gespeichert in:
| Veröffentlicht in: | Oncoimmunology 2012-05, Vol.1 (3), p.351-354 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 354 |
|---|---|
| container_issue | 3 |
| container_start_page | 351 |
| container_title | Oncoimmunology |
| container_volume | 1 |
| creator | Stolfi, Carmine Pallone, Francesco MacDonald, Thomas T. Monteleone, Giovanni |
| description | Interleukin (IL)-21, a cytokine produced by activated conventional CD4+ T lymphocytes and Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is also pro-inflammatory in many tissues and promotes colitis-associated colon cancer. Understanding the biology of IL-21 in these different situations is needed to ensure maximal therapeutic benefit. |
| doi_str_mv | 10.4161/onci.19122 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_4161_onci_19122</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826558830</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-de8b61055b46e130316e7ca8c7e3d42b9f54ade0686901c2cd31b544763c75af3</originalsourceid><addsrcrecordid>eNqFkV9rFDEUxYMotqx98QPIPokIU3Pzb2ZBBFmsLrQuiIJvIZO500YzyZrMKPvtm3XqqiCYlwTuueee_C4hj4GeC1DwIgbrzmEFjN0jpwwUqwRln-8f3wAn5CznL7QcRaXiq4fkhLGa1wrYKXm6CSMmj9NXFyoGSxeW1gSLaemGYQpxvMFkdvtH5EFvfMazu3tBPl28-bh-V11u327Wry8rK4Qcqw6bVgGVshUKgVMOCmtrGlsj7wRrV70UpkOqGrWiYJntOLRSiFpxW0vT8wV5NfvupnbAzmIYk_F6l9xg0l5H4_TfleBu9HX8rjlvWFOzYvDsziDFbxPmUQ8uW_TeBIxT1tAwJWXTlGwL8nyW2hRzTtgfxwDVB7b6wFb_ZFvET_4MdpT-IlkEL2dBmdRhbl3M1mEh-Tt8sHGG6uP1Xps0Ouvx6C_-087KKrfv19vN1RUFqj7oXXfgJec2F_qYBvMjJt_p0ex9TH0qi3RZ83985xbpwq-Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826558830</pqid></control><display><type>article</type><title>Interleukin-21 in cancer immunotherapy: Friend or foe?</title><source>PubMed Central</source><creator>Stolfi, Carmine ; Pallone, Francesco ; MacDonald, Thomas T. ; Monteleone, Giovanni</creator><creatorcontrib>Stolfi, Carmine ; Pallone, Francesco ; MacDonald, Thomas T. ; Monteleone, Giovanni</creatorcontrib><description>Interleukin (IL)-21, a cytokine produced by activated conventional CD4+ T lymphocytes and Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is also pro-inflammatory in many tissues and promotes colitis-associated colon cancer. Understanding the biology of IL-21 in these different situations is needed to ensure maximal therapeutic benefit.</description><identifier>ISSN: 2162-4011</identifier><identifier>ISSN: 2162-402X</identifier><identifier>EISSN: 2162-402X</identifier><identifier>DOI: 10.4161/onci.19122</identifier><identifier>PMID: 22737612</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Binding ; Biology ; Bioscience ; Calcium ; Cancer ; Cell ; colitis-associated colon cancer ; Cycle ; IL-17A ; IL-6 ; Landes ; Organogenesis ; Point of View ; Proteins ; STAT3 ; Tregs</subject><ispartof>Oncoimmunology, 2012-05, Vol.1 (3), p.351-354</ispartof><rights>Copyright © 2012 Landes Bioscience 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c445t-de8b61055b46e130316e7ca8c7e3d42b9f54ade0686901c2cd31b544763c75af3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382872/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382872/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22737612$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stolfi, Carmine</creatorcontrib><creatorcontrib>Pallone, Francesco</creatorcontrib><creatorcontrib>MacDonald, Thomas T.</creatorcontrib><creatorcontrib>Monteleone, Giovanni</creatorcontrib><title>Interleukin-21 in cancer immunotherapy: Friend or foe?</title><title>Oncoimmunology</title><addtitle>Oncoimmunology</addtitle><description>Interleukin (IL)-21, a cytokine produced by activated conventional CD4+ T lymphocytes and Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is also pro-inflammatory in many tissues and promotes colitis-associated colon cancer. Understanding the biology of IL-21 in these different situations is needed to ensure maximal therapeutic benefit.</description><subject>Binding</subject><subject>Biology</subject><subject>Bioscience</subject><subject>Calcium</subject><subject>Cancer</subject><subject>Cell</subject><subject>colitis-associated colon cancer</subject><subject>Cycle</subject><subject>IL-17A</subject><subject>IL-6</subject><subject>Landes</subject><subject>Organogenesis</subject><subject>Point of View</subject><subject>Proteins</subject><subject>STAT3</subject><subject>Tregs</subject><issn>2162-4011</issn><issn>2162-402X</issn><issn>2162-402X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNqFkV9rFDEUxYMotqx98QPIPokIU3Pzb2ZBBFmsLrQuiIJvIZO500YzyZrMKPvtm3XqqiCYlwTuueee_C4hj4GeC1DwIgbrzmEFjN0jpwwUqwRln-8f3wAn5CznL7QcRaXiq4fkhLGa1wrYKXm6CSMmj9NXFyoGSxeW1gSLaemGYQpxvMFkdvtH5EFvfMazu3tBPl28-bh-V11u327Wry8rK4Qcqw6bVgGVshUKgVMOCmtrGlsj7wRrV70UpkOqGrWiYJntOLRSiFpxW0vT8wV5NfvupnbAzmIYk_F6l9xg0l5H4_TfleBu9HX8rjlvWFOzYvDsziDFbxPmUQ8uW_TeBIxT1tAwJWXTlGwL8nyW2hRzTtgfxwDVB7b6wFb_ZFvET_4MdpT-IlkEL2dBmdRhbl3M1mEh-Tt8sHGG6uP1Xps0Ouvx6C_-087KKrfv19vN1RUFqj7oXXfgJec2F_qYBvMjJt_p0ex9TH0qi3RZ83985xbpwq-Q</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>Stolfi, Carmine</creator><creator>Pallone, Francesco</creator><creator>MacDonald, Thomas T.</creator><creator>Monteleone, Giovanni</creator><general>Taylor & Francis</general><general>Landes Bioscience</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120501</creationdate><title>Interleukin-21 in cancer immunotherapy</title><author>Stolfi, Carmine ; Pallone, Francesco ; MacDonald, Thomas T. ; Monteleone, Giovanni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-de8b61055b46e130316e7ca8c7e3d42b9f54ade0686901c2cd31b544763c75af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Binding</topic><topic>Biology</topic><topic>Bioscience</topic><topic>Calcium</topic><topic>Cancer</topic><topic>Cell</topic><topic>colitis-associated colon cancer</topic><topic>Cycle</topic><topic>IL-17A</topic><topic>IL-6</topic><topic>Landes</topic><topic>Organogenesis</topic><topic>Point of View</topic><topic>Proteins</topic><topic>STAT3</topic><topic>Tregs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stolfi, Carmine</creatorcontrib><creatorcontrib>Pallone, Francesco</creatorcontrib><creatorcontrib>MacDonald, Thomas T.</creatorcontrib><creatorcontrib>Monteleone, Giovanni</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncoimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stolfi, Carmine</au><au>Pallone, Francesco</au><au>MacDonald, Thomas T.</au><au>Monteleone, Giovanni</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin-21 in cancer immunotherapy: Friend or foe?</atitle><jtitle>Oncoimmunology</jtitle><addtitle>Oncoimmunology</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>1</volume><issue>3</issue><spage>351</spage><epage>354</epage><pages>351-354</pages><issn>2162-4011</issn><issn>2162-402X</issn><eissn>2162-402X</eissn><abstract>Interleukin (IL)-21, a cytokine produced by activated conventional CD4+ T lymphocytes and Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is also pro-inflammatory in many tissues and promotes colitis-associated colon cancer. Understanding the biology of IL-21 in these different situations is needed to ensure maximal therapeutic benefit.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>22737612</pmid><doi>10.4161/onci.19122</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2162-4011 |
| ispartof | Oncoimmunology, 2012-05, Vol.1 (3), p.351-354 |
| issn | 2162-4011 2162-402X 2162-402X |
| language | eng |
| recordid | cdi_crossref_primary_10_4161_onci_19122 |
| source | PubMed Central |
| subjects | Binding Biology Bioscience Calcium Cancer Cell colitis-associated colon cancer Cycle IL-17A IL-6 Landes Organogenesis Point of View Proteins STAT3 Tregs |
| title | Interleukin-21 in cancer immunotherapy: Friend or foe? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T03%3A30%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin-21%20in%20cancer%20immunotherapy:%20Friend%20or%20foe?&rft.jtitle=Oncoimmunology&rft.au=Stolfi,%20Carmine&rft.date=2012-05-01&rft.volume=1&rft.issue=3&rft.spage=351&rft.epage=354&rft.pages=351-354&rft.issn=2162-4011&rft.eissn=2162-402X&rft_id=info:doi/10.4161/onci.19122&rft_dat=%3Cproquest_cross%3E1826558830%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826558830&rft_id=info:pmid/22737612&rfr_iscdi=true |